文献速递浆细胞疾病造血干细胞移植与细胞治疗

移植前诱导治疗对新诊断POEMS综合征患者自体干细胞移植的影响

Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome.
PubMed 文献 · Leukemia · 2017-01-19

该研究分析138例新诊断POEMS综合征患者接受自体移植的数据,其中32例因严重终末器官功能障碍先接受移植前治疗。移植前治疗使15例(47%)获VEGF缓解,且早期并发症更少(OR 0.17)。移植后血液学缓解60例(50%),VEGF缓解76例(72%),5年PFS 76%,OS 94%。

要点

  • 移植前治疗使严重器官功能障碍者可行自体移植,15例(47%)获VEGF缓解。
  • 移植前治疗者早期并发症更少(OR 0.17,95%CI 0.04-0.71,P=0.015)。
  • 血液学和VEGF双缓解者5年PFS 95%,显著优于未双缓解者的61%。

核心结论

  • 移植前治疗可使严重终末器官功能障碍的POEMS综合征患者后续自体移植可行,并减少早期并发症。
  • 自体移植可获得较高的血液学、VEGF缓解率及器官功能改善,5年PFS和OS分别为76%和94%。
  • 血液学缓解、VEGF缓解尤其两者兼备与更好的PFS相关。

研究设计与样本

  • 回顾性分析本中心138例新诊断POEMS综合征接受自体移植的受试者数据。
  • 32例因严重终末器官功能障碍不适合立即移植而接受移植前治疗。

主要发现

  • 移植前治疗使15例(47%)获VEGF缓解。
  • 33例(24%)移植受者出现早期移植后并发症。
  • 多因素分析显示早期并发症危险因素包括年龄>50岁(OR 2.79,95%CI 1.09-7.14;P=0.033)、症状出现至移植时间>5年(OR 4.71,95%CI 1.10-20.18;P=0.037)和胸腔积液(OR 3.39,95%CI 1.26-9.12;P=0.016)。
  • 接受移植前治疗者早期并发症少于未接受者(OR 0.17,95%CI 0.04-0.71;P=0.015),尤其在VEGF缓解者中(OR 0.05,95%CI 0.01-0.49;P=0.010)。
  • 自体移植后血液学缓解60例(50%),VEGF缓解76例(72%),其他器官功能改善65-90%。

关键数值与推荐

  • 5年PFS为76%(95%CI 64-84%),5年OS为94%(95%CI 87-97%)。
  • 血液学缓解者5年PFS 83% vs 未缓解者66%(P=0.008)。
  • VEGF缓解者5年PFS 79% vs 未缓解者57%(P=0.021)。
  • 血液学和VEGF双缓解者5年PFS 95% vs 未双缓解者61%(P=0.004)。

临床怎么用

  • 对于因严重终末器官功能障碍不适合立即自体移植的POEMS综合征患者,可先给予移植前治疗以使后续移植可行。
  • 移植前治疗可能减少早期移植后并发症,尤其在获得VEGF缓解者中。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) is a rare plasma cell dyscrasia sometimes treated with a haematopoietic cell autotransplant. We analyzed data from 138 subjects with newly diagnosed POEMS syndrome receiving a autotransplant at our center. Thirty-two subjects with severe end-organ dysfunction ineligible for immediate autotransplant received pretransplant therapy, which made a subsequent autotransplant feasible. Pretransplant therapy resulted in vascular endothelial growth factor (VEGF) remissions in 15 (47%). Thirty-three transplant recipients (24%) had early posttransplant complications. Risk factors for these complications identified through multivariate analysis included age >50 years (odds ratio (OR) 2.79, 95% confidence interval (CI) 1.09-7.14; P=0.033), time from symptom onset to transplant >5 years (OR 4.71, 95% CI 1.10-20.18; P=0.037) and pleural effusion (OR 3.39, 95% CI 1.26-9.12; P=0.016). Subjects receiving pretransplant therapy had fewer early complications than those who did not (OR 0.17, 95% CI 0.04-0.71; P=0.015), especially in subjects with a VEGF remission (OR 0.05, 95% CI 0.01-0.49; P=0.010). Autotransplants resulted in hematological remission in 60 (50%), VEGF remissions in 76 (72%) and improvements in other organ functions (65-90%). The 5-year progression-free survival (PFS) and overall survival were 76% (95% CI 64-84%) and 94% (95% CI 87-97%), respectively. Hematological (5-year PFS 83 vs 66%, P=0.008), VEGF (5-year PFS 79 vs 57%, P=0.021) remissions and especially both (5-year PFS 95 vs 61%, P=0.004) were associated with better PFS.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Li J, Duan MH, Wang C, et al. Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome. Leukemia. 2017. PMID: 28100909. doi:10.1038/leu.2017.27

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。